Mankind Pharma Sector Top 20 Investor
Valuation
Returns
Per share
Growth · year on year
Ownership
Price and ratios are compiled from the exchange and third-party market data, cached and refreshed through the day — they are not Atlas facts and are not investment advice. Where a ratio is computed on more than one basis (for example standalone versus trailing-twelve-month), each is shown separately rather than averaged into a single number.
How this score is calculated
| Measure | Value | Scores | Source |
|---|---|---|---|
| P/E What the market pays for each rupee of earnings. Lower is cheaper — but a low P/E can also mean the market expects earnings to fall. Computed on a different basis this reads 44.10, which would score 25/100. Scored on the figure shown. |
32.87 | 50/100 | BSE |
| P/B Price against book value. Most meaningful for banks and asset-heavy businesses; software and consumer brands trade high here for good reasons. |
5.69 | 25/100 | Market data |
| ROE Return on equity — profit generated per rupee of shareholder capital. Sustained high ROE is the clearest single marker of a good business. |
13.31 | 50/100 | Market data |
| ROCE Return on capital employed — the same idea including debt, so it is harder to flatter with leverage. |
13.32 | 50/100 | Market data |
| Profit growth Year-on-year growth in profit. Weighted above sales growth because profitable growth is the harder thing to do. |
18.14 | 75/100 | Market data |
| Sales growth Year-on-year growth in revenue. |
9.61 | 50/100 | Market data |
| Promoter holding How much of the company its founders and controlling group still own. Higher usually means their money moves with yours. |
72.63 | 100/100 | Market data |
The Atlas Score is our own arithmetic on the published figures above — nothing is hidden and nothing is bought in. It weighs quality and growth at 30% each, valuation at 25% and ownership at 15%, scoring each measure against fixed bands. Growth blends third-party market data with the fiscal-year figures we file and cite ourselves, so a company we have researched more deeply scores on richer evidence. A measure we could not fetch is left out of the average rather than counted as a zero. It is a summary of the numbers, not a recommendation, not a price target, and not advice about your circumstances.
Mankind Pharma: Funding Rounds
No funding rounds tracked for Mankind Pharma yet.
Mankind Pharma: Recent Investments
| Date | Company | Round | Amount |
|---|---|---|---|
| 21 Mar 2022 | Leverage Edu | Series B | $22 Mn |
News on Mankind Pharma
No coverage of Mankind Pharma linked yet.
L Litmus · by Lapaas
Got an idea like this one? Validate it with the same 9-block framework, free.
Start Free Validation